Milbemycin Oxime + Lufenuron + Praziquantel

Verify with FDA CVM →

170 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
170
Total Reports
4
Deaths Reported
240.0%
Death Rate

Active Ingredients

Milbemycin Oxime + Lufenuron + Praziquantel

Administration Routes

OralUnknownOther

Species Affected

Dog 169
Unknown 1

Most Affected Breeds

Retriever - Labrador 32
Crossbred Canine/dog 14
Chihuahua 9
Shepherd Dog - German 8
Pit Bull 6
Shepherd Dog - Australian 6
Boxer (German Boxer) 6
Retriever - Golden 5
Corgi (unspecified) 4
Beagle 4

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 57
Vomiting 35
Other abnormal test result NOS 19
Lethargy (see also Central nervous system depression in 'Neurological') 17
Diarrhoea 12
Behavioural disorder NOS 9
Emesis 8
Lack of efficacy - NOS 6
INEFFECTIVE, HEARTWORM LARVAE 6
Seizure NOS 6
Decreased appetite 6
Lack of efficacy (endoparasite) - tapeworm 6

Outcome Breakdown

Outcome Unknown
93 (55.0%)
Recovered/Normal
39 (23.1%)
Ongoing
29 (17.2%)
Recovered with Sequela
4 (2.4%)
Died
2 (1.2%)
Euthanized
2 (1.2%)

Data Summary

Metric Value
Total adverse event reports 170
Reports involving death 4
Case-fatality rate (reported events) 240.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Milbemycin Oxime + Lufenuron + Praziquantel Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 170 adverse event reports referencing Milbemycin Oxime + Lufenuron + Praziquantel, including 4 reports in which the animal died — a 240.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Milbemycin Oxime + Lufenuron + Praziquantel. Reported administration routes include Oral, Unknown, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Milbemycin Oxime + Lufenuron + Praziquantel reports are Dog (169 reports), Unknown (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (32), Crossbred Canine/dog (14), Chihuahua (9) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Milbemycin Oxime + Lufenuron + Praziquantel are Lack of efficacy (endoparasite) - heartworm (57), Vomiting (35), Other abnormal test result NOS (19), Lethargy (see also Central nervous system depression in 'Neurological') (17). Of the 169 reports with a coded outcome, Outcome Unknown is the leading category at 55.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Milbemycin Oxime + Lufenuron + Praziquantel.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial